<?xml version="1.0" encoding="UTF-8"?>
<ref id="bb0285">
 <label>57</label>
 <element-citation publication-type="journal" id="rf0280">
  <person-group person-group-type="author">
   <name>
    <surname>Atzeni</surname>
    <given-names>F.</given-names>
   </name>
   <name>
    <surname>Sarzi-Puttini</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Botsios</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Carletto</surname>
    <given-names>A.</given-names>
   </name>
   <name>
    <surname>Cipriani</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Favalli</surname>
    <given-names>E.G.</given-names>
   </name>
  </person-group>
  <article-title>Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry</article-title>
  <source>Autoimmun Rev</source>
  <volume>12</volume>
  <year>2012</year>
  <fpage>225</fpage>
  <lpage>229</lpage>
  <pub-id pub-id-type="doi">10.1016/j.autrev.2012.06.008</pub-id>
  <pub-id pub-id-type="pmid">22796281</pub-id>
 </element-citation>
</ref>
